EXHIBIT 10.2 **** AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING AGREEMENT AGREEMENT, dated as of July 20, 2001, by and between EMBREX, INC., a North Carolina corporation ("Embrex"), and LIFESENSORS, INC., a Pennsylvania corporation...Development and Marketing Agreement • November 9th, 2001 • Embrex Inc/Nc • Biological products, (no disgnostic substances) • North Carolina
Product Development and Marketing AgreementDevelopment and Marketing Agreement • November 13th, 2001 • Cal Bay International Inc • Phonograph records & prerecorded audio tapes & disks • California
This Product Development and Marketing Agreement ("Agreement") is made and effective this July 17, 2001 by and between Advanced Environmental Technology Inc. ("AET"), a Delaware Corporation located at 32872 Bluffside Drive, Dana Point, California 92629 and Cal-Bay Controls Inc. ("CBC"), a Nevada Corporation located at 1582 Parkway Loop, Suite G, Tustin, California 92780.
WITNESSETH:Development and Marketing Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.33 DEVELOPMENT AND MARKETING AGREEMENT ----------------------------------- This DEVELOPMENT AND MARKETING AGREEMENT is made and entered into as of this 12th day of March 1999 by and between OVERLAND R.C. 29, LLC, a California Limited...Development and Marketing Agreement • July 9th, 1999 • Inco Homes Corp • Operative builders
February 2006 Amendment to Software Development and Marketing AgreementDevelopment and Marketing Agreement • February 27th, 2006 • Datawatch Corp • Services-prepackaged software
This is an amendment (the “February 2006 Amendment”) to that certain Software Development and Marketing Agreement dated as of January 19th, 1989, as amended (the “License Agreement”) by and among Datawatch Corporation, a Delaware corporation with offices located at 271 Mill Road, Quorum Office Park, Chelmsford, MA 01824 (“Datawatch”) jointly and severally with Personics Corporation, a Delaware corporation with offices located at 271 Mill Road, Quorum Office Park, Chelmsford, MA 01824 (“Personics”) (Datawatch and Personics are collectively referred to herein as “Licensee”), on the one hand, and Raymond J. Huger, a sole proprietor doing business as Math Strategies, having its principal place of business at 101 South Elm Street, Suite 212, Greensboro, North Carolina 27401 ( Huger and Math Strategies being referred to herein as “MS”). This February 2006 Amendment is effective as of February 20, 2006.
Product Development And Marketing AgreementDevelopment and Marketing Agreement • August 8th, 2021
DHeaprvraercdiaitsoorybsWtriellpreruovuesn. iIsgensagciruasmroepdhaotendichaellyr .riRvaegdeistnriabtutitlye,dsChehaanbeyepsariat lsleallitzisehmly.ile or reforests tediously when
DEVELOPMENT AND MARKETING AGREEMENTDevelopment and Marketing Agreement • May 1st, 2006 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Development and Marketing Agreement (this “Agreement”) is hereby entered into and effective as of February 22, 2006 (the “Effective Date”) by and between Spectrum Pharmaceuticals, Inc. (“Spectrum”), a Delaware corporation, with offices located at 157 Technology Drive, Irvine, California 92618 and Par Pharmaceutical, Inc. (“Par”), a Delaware corporation with offices located at 300 Tice Boulevard, Woodcliff Lake, New Jersey 07677. Spectrum and Par shall each be defined as a “Party” and together as the “Parties” under this Agreement.
Amendment No. 1 to Strategic Development and Marketing AgreementDevelopment and Marketing Agreement • April 9th, 2007 • Comverge, Inc. • Auto controls for regulating residential & comml environments
This Amendment No. 1 to the Strategic Development and Marketing Agreement (this “Amendment”) is made and entered into this 4th day of April, 2007, by and between Air Products and Chemicals, Inc. (“Air Products”) and Comverge, Inc. (“Comverge”). Comverge and Air Products are individually referred to as a “Party” or collectively as “Parties.” Capitalized terms not defined herein shall have the same meanings as assigned to them in the Agreement.
EXHIBIT 10.31 DEVELOPMENT AND MARKETING AGREEMENT ----------------------------------- This DEVELOPMENT AND MARKETING AGREEMENT is made and entered into as of this 12th day of March 1999 by and between HARWOOD PALMDALE PARTNERS I, LP, a Limited...Development and Marketing Agreement • July 9th, 1999 • Inco Homes Corp • Operative builders
Development and Marketing Agreement —Between— Boehringer Ingelheim International GmbH and InterMune Pharmaceuticals, Inc. March 23, 2001Development and Marketing Agreement • May 15th, 2001 • Intermune Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 10.19Development and Marketing Agreement • December 30th, 1996 • Epitope Inc/Or/ • In vitro & in vivo diagnostic substances • California
RIN/LCFS DEVELOPMENT and MARKETING AGREEMENTDevelopment and Marketing Agreement • January 24th, 2020 • Nebraska
Capitalized terms not otherwise defined in this Agreement have the respective meanings assigned to them in Exhibit A, which is attached hereto and is expressly incorporated herein by reference.
WITNESSETHDevelopment and Marketing Agreement • November 14th, 1997 • United Homes Inc • General bldg contractors - residential bldgs • Illinois
FIRST AMENDMENT TO THE DEVELOPMENT AND MARKETING AGREEMENTDevelopment and Marketing Agreement • March 14th, 2007 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
This First Amendment (“Amendment”) to the Development and Marketing Agreement (“Agreement”) dated February 22, 2006, by and between Spectrum Pharmaceuticals, Inc. (“Spectrum”) and Par Pharmaceutical, Inc. (“Par”) is entered into and is effective as of November 10, 2006 (“First Amendment Effective Date”), hereinafter referred to as “Party” and, collectively, as “Parties.” Capitalized terms used but not defined herein shall have the meanings given them in the Agreement.
EXHIBIT 10.87 DEVELOPMENT AND MARKETING AGREEMENT ----------------------------------- This DEVELOPMENT AND MARKETING AGREEMENT is made and entered into as of this 21st day of October 1997 and between CAPITAL MUTUAL MORENO VALLEY, LLC., a California...Development and Marketing Agreement • March 31st, 1998 • Inco Homes Corp • Operative builders
AMENDMENT NO. 1 TO AMENDED AND RESTATED COLLABORATIVE RESEARCH, DEVELOPMENT AND MARKETING AGREEMENT BETWEEN MITOTIX, INC. AND DUPONT PHARMACEUTICALS COMPANYDevelopment and Marketing Agreement • June 9th, 2004 • GPC Biotech Ag
This Amendment No. 1, effective April 3, 2000 (the “Effective Date”) is made to the Collaborative Research, Development and Marketing Agreement dated as of December 6, 1995, as amended and restated as of June 2, 1997 (the “Agreement”) between Mitotix, Inc., a Delaware corporation having its principal place of business at One Kendall Square, Building 600, Cambridge, Massachusetts 02139 (“Mitotix”) and DuPont Pharmaceuticals Company, a Delaware general partnership having its principal place of business at 974 Centre Road, Wilmington, Delaware 19807 (“DPC”).
AMENDMENT NO. 2 TO AMENDED AND RESTATED COLLABORATIVE RESEARCH, DEVELOPMENT AND MARKETING AGREEMENT BETWEEN MITOTIX, INC. AND DUPONT PHARMACEUTICALS COMPANYDevelopment and Marketing Agreement • June 9th, 2004 • GPC Biotech Ag
This Amendment No. 2, effective July 30, 2000 (the “Effective Date”) is an amendment to the Collaborative Research, Development and Marketing Agreement dated as of December 6, 1995, as amended and restated as of June 2, 1997, and as amended by Amendment No. 1 effective April 3, 2000 (collectively the “Agreement”) between GPC Biotech Inc. (formerly Mitotix, Inc.), a Delaware corporation having its principal place of business at One Kendall Square, Building 600, Cambridge, Massachusetts 02139 (“GPC”) and DuPont Pharmaceuticals Company, a Delaware general partnership having its principal place of business at 974 Centre Road, Wilmington, Delaware 19807 (“DPC”).
AMENDMENT NO. 1 TO AGREEMENT TERMINATING RESEARCH, DEVELOPMENT AND MARKETING AGREEMENTDevelopment and Marketing Agreement • November 19th, 2010 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus
This AMENDMENT NO. 1 (“Amendment No. 1”) to the AGREEMENT TERMINATING RESEARCH, DEVELOPMENT AND MARKETING AGREEMENT (“Termination Agreement”), is entered into as of November 1, 2010, between BioMimetic Therapeutics, Inc., a Delaware corporation (formerly known as BioMimetic Pharmaceuticals, Inc.) (“BMTI”), and Luitpold Pharmaceuticals, Inc., a New York corporation (“Luitpold”).
Product Development And Marketing AgreementDevelopment and Marketing Agreement • June 22nd, 2022
nesisymmipcaHthaermticawn hqeunadCrluepmleenotr sausbsduuacgtegsaopmineglsyu?pUerncplalesasseesdhaanradspsewdltye,rhJoawmeevseorntrfeeeedzeDsoovmbelujdugtteinrgeasroweamrdboarruanshsiendgglye!d. Is Thaddus
AMENDMENT NO. 3 TO AMENDED AND RESTATED COLLABORATIVE RESEARCH, DEVELOPMENT AND MARKETING AGREEMENT BETWEEN MITOTIX, INC. AND DUPONT PHARMACEUTICALS COMPANYDevelopment and Marketing Agreement • June 9th, 2004 • GPC Biotech Ag
This Amendment No. 3, effective October 1, 2000 (the “Effective Date”) is an amendment to the Collaborative Research, Development and Marketing Agreement dated as of December 6, 1995, as amended and restated as of June 2, 1997, and as amended by Amendment No. 1 effective April 3, 2000, and as amended by Amendment No. 2 effective July 30, 2000 (collectively the “Agreement”) between GPC Biotech Inc. (formerly Mitotix, Inc.), a Delaware corporation having its principal place of business at One Kendall Square, Building 600, Cambridge, Massachusetts 02139 (“GPC”) and DuPont Pharmaceuticals Company, a Delaware general partnership having its principal place of business at 974 Centre Road, Wilmington, Delaware 19807 (“DPC”).
WITNESSETHDevelopment and Marketing Agreement • November 14th, 1997 • United Homes Inc • General bldg contractors - residential bldgs • Illinois
AMENDMENT NO. 1 TO CRACKLE, INC. CONFIDENTIAL CHROMECAST DEVELOPMENT AND MARKETING AGREEMENTDevelopment and Marketing Agreement • October 23rd, 2014
This Amendment No. 1 (“Amendment”) effective as of the date the Amendment is signed by Google (the “Amendment Effective Date”), is made between Google Inc., a Delaware corporation ("Google") and Crackle, Inc. (“Partner”), a Delaware corporation. This Amendment amends the Crackle, Inc. Confidential Chromecast Development and Marketing Agreement (the “Agreement”) between the Parties with an Effective Date of December 30, 2013. Capitalized terms that are used but not defined herein shall be as defined in the Agreement. In consideration of the mutual covenants contained herein, Google and Partner agree to the following additions and revisions:
EXHIBIT 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED....Development and Marketing Agreement • March 24th, 2000 • Noosh Inc • Services-business services, nec
